Mental Health, Mental Illness & Addiction: CMA Submission to the Standing Committee on Social Affairs, Science and Technology

https://policybase.cma.ca/link/policy1950

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAST REVIEWED</td>
<td>2012-03-03</td>
</tr>
<tr>
<td>DATE</td>
<td>2005-04-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Population health, health equity, public health, Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

---

---
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

Cannabis for Medical Purposes

Cannabis for Medical Purposes

The Canadian Medical Association (CMA) recognizes the serious and complex challenges that cannabis presents for patients. The CMA has been active since the 1990s in addressing the potential public health and social implications of cannabis use.

The CMA notes that cannabis is a Schedule II drug under the Controlled Drugs and Substances Act. The use of cannabis by medical practitioners is directly regulated by the College of Physicians and Surgeons of Ontario and the other provincial bodies that regulate medical practice. The CMA supports the regulation of cannabis by the College of Physicians and Surgeons of Ontario and the other provincial bodies.

The CMA recognizes the potential benefits of cannabis for medical purposes and acknowledges the need for further research to assess the safety and efficacy of cannabis products.

The CMA recommends that the use of cannabis for medical purposes be subject to appropriate oversight and regulation by the appropriate regulatory bodies.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.

The CMA recognizes the need for continued education and awareness among healthcare providers and the public regarding the use of cannabis for medical purposes.

The CMA urges healthcare providers to consider the potential benefits and risks of cannabis for medical purposes and to provide evidence-based information to their patients.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recognizes the need for further research to assess the safety and efficacy of cannabis products and to develop evidence-based guidelines for their use.

The CMA supports the development of policies and guidelines that protect the public and healthcare providers while allowing for the safe and effective use of cannabis for medical purposes.

The CMA recommends that healthcare providers involved in the use of cannabis for medical purposes receive ongoing training and education on the safe and effective use of cannabis.

The CMA supports the development of evidence-based guidelines for the safe and effective use of cannabis products.
MEDICATION USE AND SENIORS
(UPDATE 2017)

The Canadian Medical Association recommends that pharmacists and doctors assess the needs and preferences of seniors when providing medication information and advice. The use of medication by seniors should be reviewed as part of a comprehensive assessment of an individual's health status, including their overall health goals, lifestyle, and medication history. Medication use by seniors can have significant impacts on their quality of life, health, and well-being. Pharmacists and doctors should carefully consider the potential risks and benefits of medications for seniors, taking into account their unique characteristics, including age, gender, body weight, and medical conditions.

CMA Policybase - Canadian Medical Association
CMA’s Submission to the House of Commons Standing Committee on Health:
Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE: Parliamentary submission
DATE: 2012-03-29
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology - Prescription Drugs: Clinical Trials and Approval

https://policybase.cma.ca/link/policy10437

POLICY TYPE: Parliamentary submission
DATE: 2012-05-09
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology - Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE
Parliamentary submission

DATE
2012-10-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada
https://policybase.cma.ca/link/policy10756

POLICY TYPE
Policy document

LAST REVIEWED
2017-03-04

DATE
2013-05-25

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health
https://policybase.cma.ca/link/policy11035

POLICY TYPE
Parliamentary submission

DATE
2013-11-27

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114

POLICY TYPE  Response to consultation
DATE  2014-03-17
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE
Parliamentary submission

DATE
2014-03-26

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase

https://policybase.cma.ca/link/policy11129

POLICY TYPE
Parliamentary submission

DATE
2014-05-15

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Health risks and harms associated with the use of marijuana
https://policybase.cma.ca/link/policy11138

POLICY TYPE  Parliamentary submission
DATE  2014-05-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE
Parliamentary submission

DATE
2014-06-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE  Response to consultation
DATE  2014-07-11
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE  Response to consultation
DATE  2014-08-26
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE  Parliamentary submission
DATE  2014-10-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes

POLICY TYPE: Policy document
LAST REVIEWED: 2020-02-29
DATE: 2015-02-28
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE  Parliamentary submission
DATE  2015-05-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents